Norepinephrine Sopharma (Noradrenaline Tartrate)

Norepinephrine binds directly to alpha‑1 and beta‑1 adrenergic receptors. Alpha‑1 activation causes peripheral blood vessels to constrict, increasing systemic vascular resistance. Beta‑1 activation stimulates the heart, raising heart rate and contractility, which together elevate arterial pressure and enhance organ perfusion.

The dose of Norepinephrine Sopharma is individualized by the prescribing clinician. It is typically started at a low infusion rate and titrated to achieve a target mean arterial pressure, based on the patient’s condition and response.

The safety of norepinephrine in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Norepinephrine is often preferred as a first‑line vasopressor because it provides strong alpha‑1 mediated vasoconstriction with modest beta‑1 activity, balancing blood pressure support and cardiac output. Alternatives such as dopamine or phenylephrine have different receptor profiles and may be chosen based on specific hemodynamic goals.

Norepinephrine Sopharma must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as an injectable solution for intravenous infusion. It is typically diluted in a compatible carrier fluid and delivered through a calibrated infusion pump, allowing precise titration to the desired blood pressure target.

Serious risks include severe hypertension, myocardial ischemia, and tissue necrosis if the drug extravasates from the vein. Continuous hemodynamic monitoring and careful infusion site inspection are essential to detect and manage these complications promptly.

Patients with uncontrolled hypertension, known hypersensitivity to norepinephrine or its excipients, and those in whom the risks of excessive vasoconstriction outweigh benefits should not receive the drug. Clinical judgment is required for each individual case.